We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
+3.56%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$126M
AUM Growth
-$8.56M
(-6.4%)
Cap. Flow
-$3.54M
Cap. Flow % of AUM
Cap. Flow %
-2.81%
Top 10 Holdings %
Top 10 Hldgs %
94.04%
Holding
17
New
–
Increased
–
Reduced
2
Closed
1
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.5
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$2.59M |
| 2 |
Senseonics Holdings Inc
SENS
|
+$920K |
| 3 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
+$21.7K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CRISPR Therapeutics
CRSP
$4.97B
| $39M | 31.01% |
2,444,809
-157,005
| -6% | -$2.59M |
2016 Q4
2 quarters
|
|
|
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $31.3M | 24.89% |
1,300,432
-981
| -0.1% | -$21.7K |
2014 Q4
10 quarters
|
|
|
SIEN
3
DELISTED
Sientra, Inc.
SIEN
| $21.3M | 16.97% |
219,901
| – | – |
2014 Q4
10 quarters
|
|
4
DELISTED
Cymabay Therapeutics
CBAY
| $9.22M | 7.33% |
1,600,000
| – | – |
2015 Q3
7 quarters
|
|
|
CASC
5
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $3.43M | 2.73% |
925,000
| – | – |
2017 Q1
1 quarter
|
|
|
IMDZ
6
DELISTED
Immune Design Corp.
IMDZ
| $3.4M | 2.71% |
352,300
| – | – |
2016 Q2
4 quarters
|
|
7
Protara Therapeutics
TARA
$147M
| $3.03M | 2.41% |
50,447
| – | – |
2014 Q4
10 quarters
|
|
|
CHMA
8
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $2.91M | 2.32% |
2,080,595
| – | – |
2015 Q3
7 quarters
|
|
9
Cellectis
CLLS
$109M
| $2.57M | 2.04% |
100,000
| – | – |
2015 Q4
6 quarters
|
|
10
DELISTED
Dermira, Inc.
DERM
| $2.04M | 1.62% |
70,000
| – | – |
2015 Q3
7 quarters
|
|
|
EVAR
11
DELISTED
Lombard Medical, Inc.
EVAR
| $1.81M | 1.44% |
3,473,452
| – | – |
2014 Q3
11 quarters
|
|
12
Ocugen
OCGN
$238M
| $1.58M | 1.26% |
14,815
| – | – |
2016 Q3
3 quarters
|
|
13
Aurinia Pharmaceuticals
AUPH
$2.23B
| $1.54M | 1.23% |
252,129
| – | – |
2017 Q1
1 quarter
|
|
|
INNL
14
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
| $1.22M | 0.97% |
537,235
| – | – |
2015 Q2
8 quarters
|
|
|
ADAP
15
DELISTED
Adaptimmune Therapeutics
ADAP
| $1.12M | 0.9% |
250,000
| – | – |
2015 Q4
6 quarters
|
|
|
NOVN
16
DELISTED
Novan, Inc. Common Stock
NOVN
| $215K | 0.17% |
5,337
| – | – |
2016 Q3
3 quarters
|
|
|
17
Senseonics Holdings Inc
SENS
$503M
| – | – |
-25,844
| Closed | -$920K | – |
|
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q2 2017 Portfolio in Review
As of Q2 2017, Abingworth held 17 positions worth $126M, down 6.4% from $134M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
Abingworth's Q2 2017 filing shows 2 reduced and 1 closed positions. The largest sale was CRISPR Therapeutics, an estimated $2.59M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Abingworth's biggest Q2 2017 reduction was CRISPR Therapeutics, cutting an estimated $2.59M.
- Abingworth fully exited Senseonics Holdings Inc in Q2 2017, selling an estimated $920K.
- Abingworth's ten largest holdings make up 94% of its $126M portfolio in Q2 2017.
- Abingworth opened 0 new positions and closed 1 in Q2 2017.
- Abingworth's portfolio value fell 6.4% quarter-over-quarter to $126M.
Based on Abingworth's 13F filing for Q2 2017, filed 14 Aug 2017.